A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Douglas W. SborovDivision of Hematology, Department of Internal Medicine, University of Utah, Salt Lake City, UT, USA;

Alessandro CanellaComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;

Erinn M. HadeCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA;

Xiaokui MoCenter for Biostatistics, Department of Biomedical Informatics, The Ohio State University, Columbus, OH, USA;

Soun KhounthamComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;

Jiang WangComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA;

Wenjun NiDivision of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA;

Ming PoiComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; ;Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA;

Christopher CossComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; ;Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA;

Zhongfa LiuDivision of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA;

Mitch A. PhelpsComprehensive Cancer Center, The Ohio State University, Columbus, OH, USA; ;Division of Pharmaceutics, College of Pharmacy, The Ohio State University, Columbus, OH, USA;

Amir MortazaviDivision of Medical Oncology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Leslie AndritsosDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Robert A. BaiocchiDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Beth A. ChristianDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Don M. BensonDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Joseph FlynnDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Pierluigi PorcuDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

John C. ByrdDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA;

Flavia PichiorriComprehensive Cancer Center, City of Hope, Duarte, CA, USA

Craig C. HofmeisterDivision of Hematology, Department of Internal Medicine, The Ohio State University, Columbus, OH, USA; Correspondence[email protected]

show all

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Supplementary_text__28-Feb-2017_.docx

Supplementary data

ICMJE Form for Disclosure of Potential Conflicts of Interest

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas

Supplementary_text__28-Feb-2017_.docx

Supplementary data

ICMJE Form for Disclosure of Potential Conflicts of Interest

Reprints and Corporate Permissions

Academic Permissions

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date